Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Novartis (NVS) Receives a New Rating from Bernstein

Tipranks - Tipranks - Fri Mar 20, 3:50PM CDT

Novartis received a Hold rating and price target from Bernstein analyst Justin Smith today.

Claim 70% Off TipRanks Premium

According to TipRanks, Smith is a 4-star analyst with an average return of 12.7% and a 70.83% success rate. Smith covers the Healthcare sector, focusing on stocks such as Roche Holding AG, GlaxoSmithKline, and AstraZeneca.

In addition to Bernstein, Novartis also received a Hold from Berenberg Bank’s Kerry Holford in a report issued on March 6. However, on March 11, Argus Research upgraded Novartis (NYSE: NVS) to a Buy.

See Insiders’ Hot Stocks on TipRanks >>

Based on Novartis’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $13.33 billion and a net profit of $2.41 billion. In comparison, last year the company earned a revenue of $13.56 billion and had a net profit of $2.82 billion

Read More on NVS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).